Somaxon announces nonreceipt of Paragraph IV certification for generic Silenor ANDA

Links shared publicly online about this topic.

791
total visits

Somaxon announces nonreceipt of Paragraph IV certification for generic Silenor ANDA

Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today announced that the website of the U.S. Food and Drug Administration (FDA) indicates that an Abbreviated New Drug Application (ANDA) for a generic version of Silenor® (doxepin) 3 mg and 6

View full resource at news-medical.net

Tags: Nervous System, Disease and Condition, Diet and Nutrition, Drug, Pharma, FDA, disease